ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg may be appropriate for any patient with persistent diabetic macular edema (DME)

Consider ILUVIEN for the following patients with DME:

Consider ILUVIEN for your patients with persistent DME who have not achieved good visual acuity (VA)

In the real-world USER Study, 20% of ILUVIEN-treated eyes had VA worse than 20/100 at the time of treatment1

In these eyes, treatment with ILUVIEN improved VA and reduced the number of DME treatments on average1

USER data: VA and DME treatment frequency before and after ILUVIEN in patients
with VA worse than 20/100 at the time of treatment (n = 32 eyes)1,a

aMean follow-up after ILUVIEN across the total USER population (N = 160) was 403 days, with 102 eyes followed up for 6 months, 92 for 12 months, and 88 for 15 months. The number of patients available for follow-up at each time point varied.
bP<0.001 vs treatment frequency before ILUVIEN.
cP=0.026 vs treatment frequency before ILUVIEN.

Real-world data from the USER Study confirm the efficacy
of ILUVIEN in a variety of patients with persistent DME.

PATIENTcase study
case study

Review a case study of treatment with ILUVIEN following
recurrent retinal edema that caused reduced VA.